Table 1.
Baseline characteristics of patients with severe aortic stenosis: procedural and postprocedural data (N = 30)
| Variable | Value |
|---|---|
| Age, y, median (IQR) | 83.0 (79.0–85.3) |
| Male, no. (%) | 8 (26.7%) |
| Body mass index, kg/m2, median (IQR) | 27.1 (25.4–30.0) |
| Arterial hypertension (only β‐blocker), no. (%) | 24 (80.0%) |
| Diabetes mellitus, no. (%) | 14 (46.7%) |
| Hyperlipidemia, no. (%) | 308 (100.0%) |
| Previous pacemaker, no. (%) | 0 (0.0%) |
| Atrial fibrillation, no. (%) | 0 (0.0%) |
| Aortic valve parameters | |
| TG max, mm Hg, median (IQR) | 80.0 (72.0–102.0) |
| TG mean, mm Hg, median (IQR) | 46.0 (42.0–53.0) |
| Aortic valve area, cm2, median (IQR) | 0.6 (0.6–0.9) |
| LVEF, %, median (IQR) | 61.5 (50.0–65.0) |
| Risk of surgery | |
| Logistic EuroScore I [%], median (IQR) | 13.1 (9.5–23.2) |
| Society of Thoracic Surgeons Score [%], median (IQR) | 5.6 (4.0–13.7) |
| Device implanted, no. (%) | |
| Edwards Sapien, Sapien XT, Sapien 3 | 13 (46.7%) |
| Medtronic CoreValve, Evolut | 8 (26.6%) |
| Jena Valve | 3 (10.0%) |
| Lotus | 5 (16.7%) |
| Aortic regurgitation after TAVI, no. (%) | |
| None | 24 (80.0%) |
| Grade 1 | 6 (20.0%) |
| Grade 2 | 0 (0.0%) |
| Grade 3 | 0 (0.0%) |
| TG max after TAVI, mm Hg, median (IQR) | 12.0 (10.0–20.3) |
| TG mean after TAVI, mm Hg, median (IQR) | 7.0 (5.3–11.8) |
Abbreviations: IQR, interquartile range; LVEF, left ventricle ejection fraction; TAVI, transcatheter aortic valve implantation; TG, transaortic gradient.